Bio-Rad Laboratories Focuses on Digital PCR for Growth and Market Expansion

Bio-Rad Laboratories is pursuing a multi-year effort to improve growth, expand margins, and strengthen free cash flow. The company is centering this strategy on its Digital PCR business, which allows for absolute quantitation and is useful for rare-event detection in fields like oncology and minimal residual disease. Bio-Rad's droplet-based approach and its library of over 400,000 assays support its market position.

The focus on Digital PCR is a key area for Bio-Rad Laboratories to drive its business strategy. The company views next-generation sequencing and PCR as complementary technologies, noting that research labs often utilize multiple methods depending on the application.

Strategic acquisitions and product launches are driving growth for Bio-Rad Laboratories in the life science ddPCR and clinical diagnostics markets. Illumina and Bio-Rad Laboratories collaborate on advanced life science technologies.